The antimycobacterial activities of a new rifampin (RIF) derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9), against 20 susceptible and multidrug-resistant strains of Mycobacterium tuberculosis and 20 Mycobacterium avium complex (MAC) strains were investigated. The radiometric MICs of T9 for M. tuberculosis were significantly lower than those of RIF. The MICs of T9 and RIF at which 90% of the RIF-susceptible strains were inhibited were <0.25 and <0.5 g/ml, respectively. Interestingly, T9 had lower MICs against some RIF-resistant M. tuberculosis strains. T9 had better activity against MAC strains, and the MIC at which 90% of the MAC strains were inhibited was <0.125 g/ml, and that of RIF was <2.0 g/ml. T9 also showed high in vitro bactericidal and intracellular activities which were significantly superior to those of RIF against both M. tuberculosis and MAC strains. More importantly, T9 showed excellent in vivo activity against M. tuberculosis H37Rv compared with that of RIF in both the lungs and spleens of C57BL/6 mice, indicating the potential therapeutic value of T9 in the treatment of mycobacterial infections.
In recent years, several rifamycin derivatives (including rifapentine, rifabutin, and KRM-1648, etc.) have been investigated for their activities against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) in in vitro, macrophage, and animal models (1, 3, 8, 10) . In a similar attempt, the Chemical Pharmaceutical Research Institute, Sofia, Bulgaria, has developed a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV, which was called T9 (Fig. 1) . Investigations conducted by the developers of the drug have indicated good therapeutic activity, lack of toxicity, and favorable pharmacokinetics and bioavailability in experimental animals (4, 5) . In this communication we report the antimycobacterial activities of T9 against M. tuberculosis and MAC.
MATERIALS AND METHODS
Drugs. T9 was supplied by the Chemical Pharmaceutical Research Institute (NIHFI); rifampin (RIF) was purchased from Sigma Chemical Company (St. Louis, Mo.). For in vitro studies, stock solutions of the drugs were prepared in dimethyl sulfoxide and stored at Ϫ80ЊC. Required dilutions were made in distilled water for inoculation to BACTEC vials and for macrophage studies. For in vivo studies, the drugs were suspended in sterile distilled water containing 0.5% carboxymethyl cellulose. Drug suspensions were made every week and stored at Ϫ10ЊC until use.
Mycobacteria. M. tuberculosis strains used in the study consisted of susceptible and multidrug-resistant (MDR) strains of M. tuberculosis. The sources of the strains and detailed drug susceptibility patterns have been described previously (8) . M. avium strains used in the study were smooth, transparent colonial forms isolated from AIDS patients.
Macrophages. Intracellular activity of T9 was determined with the J774A.1 mouse macrophage cell line, which was obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.
Mice. Four-to six-week-old C57BL/6 mice of either sex were obtained from Jackson Laboratories (Bar Harbor, Maine). Mice were quarantined for 1 week after being obtained and were caged (five mice per cage) in microisolator cages during the experiment.
Determination of MICs. MICs were determined by the radiometric (BACTEC) method as described previously (8) . The required M. tuberculosis strains were grown in 7H9 broth for 3 to 4 weeks, adjusted to McFarland no. 1 turbidity, and used as inocula. With MAC strains, after 2 weeks of growth in 7H9 broth the strains were adjusted to McFarland no. 1 turbidity and 1/100 dilutions of the suspensions were used as inocula. All drug-containing vials were inoculated with 0.1 ml of the bacterial suspensions prepared as described above. For each test, two drug-free controls were also included, one inoculated with 0.1 ml of the suspension used for drug-containing vials and the other inoculated with 0.1 ml of a 1/100 dilution of the suspension. The vials were incubated at 37ЊC and read in the BACTEC 460 reader (Johnston Labs, Towson, Md.) every day until the growth index (GI) in the 1/100 dilution control reached Ն30 and showed an increase of at least 10 for three consecutive days. The MIC was defined as the lowest concentration of the drug that caused an increase in the GI of equal to or less than that of the 1/100 dilution control vial. Whenever the MIC of the drug for any of the strains fell outside the initial range used, the test was repeated with higher or lower concentrations to determine the endpoints. The highest and the lowest concentrations tested were 8.0 and 0.015 g/ml, respectively.
Determination of MBC. Bactericidal activity was determined in 7H9 broth containing several twofold dilutions of T9 and RIF (8) . Each of the drugcontaining tubes and a drug-free control tube were inoculated with 0.1 ml of mycobacterial suspension adjusted to McFarland no. 1 turbidity. The tubes were incubated at 37ЊC on a roller drum protected from light. After 8 to 10 days of incubation, when the control tube showed visible turbidity, those drug-containing tubes showing no turbidity were appropriately diluted (to below the MIC, to prevent carryover of the drug) and 0.1 ml of the diluted samples was plated on 7H11 agar plates. The numbers of CFU were read after 3 weeks of incubation. The lowest concentration of the drug that killed 99% of the organisms was considered the MBC of the drug (6) .
Determination of intracellular drug activities. Test organisms were grown for 2 to 3 weeks in 7H9 broth containing 10% OADC and 0.05% Tween. The growths were washed twice with saline and adjusted to McFarland no. 1 turbidity, and M. tuberculosis H37Rv and MAC strain 101 were diluted 1/10 and 1/20, respectively, in Dulbecco's modified Eagle's medium. Twenty-four-well tissue culture chambers were seeded with 10 6 J774A.1 cells per ml per well and incubated at 37ЊC in a 5% CO 2 atmosphere. After 2 h, the macrophage monolayers were washed with Hanks balanced salt solution to remove nonadherent cells and were infected with 1.0 ml of mycobacterial suspension (containing approximately 10 7 bacteria per ml). After 2 h of incubation, nonphagocytosed organisms were removed by washing three times with warm Hanks balanced salt solution. The cells were replaced with fresh Dulbecco's modified Eagle's medium with 1% fetal bovine serum containing different concentrations (0.5 and 0.125 g/ml) of T9 or RIF. Control chambers containing only tissue culture medium were included. The tissue culture plates were incubated at 37ЊC in 5% CO 2 . Infected macro-phages were either continuously exposed to the drugs for 4 days or exposed for only 24 h and replaced with fresh drug-free Dulbecco's modified Eagle's medium. In either case, at 0 and 4 days postinfection macrophages in triplicate wells were lysed with 0.25% sodium dodecyl sulfate (SDS). The number of viable organisms in each group was determined by injecting aliquots of the lysates into BACTEC vials and determining the GI after 24 h of incubation (9) .
Determination of in vivo activity. The chemotherapeutic activity of T9 was investigated against only experimental tuberculosis. Mice were infected intravenously, each via a caudal vein, with 10 6 CFU of M. tuberculosis H37Rv per mouse. One day after infection, five mice were killed to obtain baseline CFU counts in the organs. The rest of the mice were divided into six groups; animals in groups 1, 2, 3, and 4 were dosed with 40, 20, 10, and 5 mg of T9 per kg of body weight, respectively. Mice in group 5 were dosed with 20 mg of RIF per kg. All drugs were given by oral gavage in 0.2-ml volumes 5 days a week for 8 weeks. Animals in group 6 served as the untreated infected controls.
Mortalities in each group were recorded during the course of the experiment. Five mice in each group were killed at 4 and 8 weeks following treatment. The animals to be killed at each time point were not treated for at least 24 h prior to sacrifice. Lungs and spleens were collected aseptically, weighed, and homogenized in 10-ml volumes of saline in a VirTis tissue homogenizer. The CFU counts in the homogenates were determined as described previously (7), and each result was expressed as the log CFU per gram of tissue.
Statistical analysis. The data on intracellular and in vivo activities were analyzed with Student's t test.
RESULTS
MICs of T9 and RIF. The MICs of T9 and RIF for M. tuberculosis strains are shown in Table 1 . Out of 20 strains tested, 9 were resistant to RIF, 6 of which were MDR strains. Of the 11 RIF-susceptible strains, 6 were resistant to other drugs. A significant proportion of RIF-susceptible strains (8 out of 11) showed lower MICs (Յ0.06 g/ml) with T9 than with RIF. Upon retesting of five strains for which the MICs were .06 g/ml to determine the endpoints, the MICs for two strains were Յ0.015 g/ml and the MICs for the other three strains were 0.03 g/ml. The MICs of RIF were lower than those of T9 for only 2 of 11 strains. With T9, the MICs at which 90 and 50% of the strains were inhibited (MIC 90 and MIC 50 , respectively) were Յ0.25 and Յ0.06 g/ml, respectively. On the other hand, the MIC 90 and MIC 50 of RIF were Յ0.5 and Յ0.125 g/ml, respectively. For five out of nine RIF-resistant strains, the MICs of T9 were less than those of RIF. In general, the MICs of T9 were two-to eightfold lower than those of RIF for most of the M. tuberculosis strains tested. With MAC strains ( Table 2 ) the MICs of T9 ranged from Յ0.015 to 0.25 g/ml, with the MIC 90 being Յ0.125 g/ml. The MICs of RIF for these strains ranged from Ͼ8.0 to 0.015 g/ml, with the MIC 90 being Ͼ8.0 g/ml. The MIC 50 s of T9 and RIF for MAC strains were Յ0.06 and Յ0.5 g/ml, respectively. Similar to the activity it showed against M. tuberculosis, T9 showed MICs severalfold lower compared with those of RIF.
MBCs of T9 and RIF. The bactericidal concentrations of T9
for four out of five strains of M. tuberculosis and MAC were two-to fourfold lower than those of RIF. The MBCs of T9 for M. tuberculosis strains ranged from 0.12 to 0.5 g/ml, and those of RIF ranged from 0.25 to 1.0 g/ml (Table 3) .
FIG. 2. Intracellular activities of T9
and RIF against M. tuberculosis and M. avium. J774A.1 macrophage monolayers were infected with mycobacterial suspensions and exposed to different concentrations of either drug for 4 days (or 24 h followed by replacement with fresh medium [see Table 4 ]). At the end of 4 days of incubation at 37ЊC, macrophages were lysed with 0.25% SDS. The lysates were injected into BACTEC 12B vials, and the GIs were determined. s, control; E, T9 at 0.125 g/ml; F, T9 at 0.5 g/ml; Ç, RIF at 0.125 g/ml; å, RIF at 0.5 g/ml. a Activities were determined after 24-h exposures to drugs in J774A.1 cells. GIs were determined by the BACTEC method (see legend to Fig. 2 for details) . Intracellular activities. T9 at both 0.125-and 0.5-g/ml concentrations caused significant reductions of intracellular growth of M. tuberculosis H37Rv as well as MAC strain 101 after 4 days of continuous exposure to the bacteria (Fig. 2) . RIF at similar concentrations and exposure times showed moderate activities, which were lower than those of T9 against both the organisms. The reductions of intracellular M. tuberculosis and M. avium growth by T9 were statistically significant at both the concentrations compared with those by RIF (P Ͻ 0.001). Similarly, T9 showed better activity than RIF even after a single pulsed exposure (24 h) of M. tuberculosis to the drugs (Table  4) .
In vivo activity of T9 against M. tuberculosis H37Rv. For mice treated with 40 and 20 mg of T9 per kg, tubercle bacilli could not be detected at 4 weeks in either lungs or spleens (Table 5 ). With the 10-mg/kg dose, at the fourth week mycobacteria were detectable in only three out of five mice and the mean log CFU per gram of tissue in the lungs and spleens of these animals were 3.37 and 3.49, respectively. After 8 weeks of treatment, only one out of five mice had 2.49 log CFU/g in the lungs and two out of five mice had a mean Ϯ standard deviation of 4.21 Ϯ 1.44 log CFU/g in the spleen; no organisms were detected in the rest of the mice. Even at the 5-mg/kg dose, T9 caused significant reductions of CFU, compared with the 20-mg/kg dose of RIF, in both lungs and spleens. After 8 weeks of treatment with RIF (20 mg/kg), there was a reduction of only 1.97 log CFU/g in the lungs and 1.46 log CFU/g in the spleens; on the other hand, T9 at the 5-mg/kg dose caused reductions of 3.99 and 3.13 log CFU/g in the lungs and spleens, respectively.
DISCUSSION
The recent increase in tuberculosis cases due to MDR strains has prompted the vigorous search for new drugs for the treatment of such infections. To reach this objective, a large number of RIF derivatives have been investigated for improved activities. One such introduction is T9, which is chemically 3-(4-cinnamyl-1-piperazinyl iminomethyl) rifamycin SV (Fig. 1) .
Our study confirms and considerably extends the early preliminary claims about the in vitro activities of T9 against M. tuberculosis and MAC. In comparison with RIF, the compound had severalfold lower MICs against susceptible strains as well as some RIF-resistant strains of M. tuberculosis, and one of the nine RIF-resistant strains was susceptible. Furthermore, T9 inhibited the RIF-resistant strains of MAC. The superior intracellular activities of T9 against M. tuberculosis and MAC compared with those of RIF underscore the potential usefulness of T9 against infections with these organisms.
The chemotherapeutic activity of T9 against experimental tuberculosis in C57BL/6 mice is also very encouraging. No organisms could be detected in either lungs or spleens of the mice after treatment with 20-or 40-mg/kg doses of T9 for 8 weeks. The activity of T9 was much superior to that of RIF, even at 10-and 5-mg/kg doses. Preliminary pharmacological studies of T9 with mice showed that after a dose of 10 mg/kg, the maximum concentration in plasma was 9.33 g/ml, with a time to maximum concentration in plasma of 4.93 h and a half-life of 34.75 h (3). At similar doses of RIF administered to mice, the maximum concentration in plasma observed was 7.85 g/ml at 1 h (2). Pharmacokinetic studies by Tomioka et al. (11) have shown maximum concentrations in plasma of 0.60, 12.73, and 0.92 g/ml for KRM-1648, RIF, and rifabutin, respectively, for mice receiving 20-mg/kg doses of each of the compounds. The comparison of the pharmacokinetics of some of the RIF derivatives with respect to their MICs against mycobacteria indicates that T9 has good therapeutic value.
Overall, the excellent in vitro, intracellular, and in vivo activities of T9 as well as its promising bioavailability warrant its potential usefulness in the treatment of mycobacterial infections. Further in vivo studies with both M. tuberculosis and MAC, especially in combination with other drugs, are needed to establish the usefulness of T9 in the chemotherapy of mycobacterial diseases. a The sensitivities of detection were 1,000 and 100 CFUs per organ at weeks 4 and 8, respectively. No CFUs were detectable in either organ at any time point with T9 doses of 40 and 20 mg/kg. *, P Ͻ 0.001, compared with RIF group; **, P Ͻ0.001, compared with control group.
b Determined from CFU counts from three mice. c Determined from CFU count from one mouse. d Determined from CFU counts from two mice.
